Sudeep Pharma Limited has announced its Q2FY26 results presentation and earnings call, demonstrating the company's commitment to transparent investor communication following its successful IPO listing on BSE and NSE on November 28, 2025.

Conference Call Details

The company has scheduled its earnings call for Monday, December 22, 2025, at 11:30 a.m. to discuss operational and financial performance for the quarter and half-year ended September 30, 2025.

Regulatory Compliance

Sudeep Pharma has filed the necessary documentation with both National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the SEBI (LODR) Regulations, 2015. The company's communication, dated December 21, 2025, follows its earlier intimation dated December 15, 2025, regarding the earnings call schedule.

Company Information

The pharmaceutical company operates from its registered office at 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, and maintains its corporate office at 601, 602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021, Gujarat.

Investor Access

The Q2FY26 result presentation and earnings call invite are available on the company's official website at https://www.sudeeppharma.com/ . This accessibility ensures that all stakeholders can access relevant financial information and participate in the earnings discussion.

The announcement was signed by Dimple Mehta, Company Secretary and Compliance Officer (M.No.: F13184), emphasizing the company's adherence to corporate governance standards and regulatory requirements.

Sudeep Pharma Limited has announced its Q2 financial results, revealing significant pressure on profitability metrics despite revenue growth. The pharmaceutical company's consolidated financial performance shows margin compression across key operational parameters during the quarter.

Financial Performance Overview

The company's Q2 results demonstrate challenging operational dynamics with declining profitability metrics. While revenue maintained positive momentum, both EBITDA and net profit faced substantial pressure during the reporting period.

EBITDA Performance Analysis

Sudeep Pharma's EBITDA declined significantly to ₹55.50 crores in Q2 compared to ₹63.50 crores in the corresponding quarter of the previous year. This represents a substantial decrease of ₹8.00 crores or 12.6% on a year-on-year basis, indicating operational challenges during the quarter.

Margin Compression Trends

The company's EBITDA margin contracted sharply to 34.09% in Q2 from 42.66% in the same quarter last year. This margin compression of 857 basis points reflects significant pressure on operational efficiency and cost management, despite the company's ability to grow its top-line revenue.

Revenue and Profitability Dynamics

Sudeep Pharma achieved revenue growth of 6.7% to ₹162.80 crores from ₹152.60 crores year-on-year. However, the company struggled to maintain profitability levels. The consolidated net profit declined to ₹45.70 crores compared to ₹48.70 crores in the previous year, representing a 6.2% decrease.

Key Financial Highlights

The Q2 results underscore the challenges facing the pharmaceutical company in maintaining operational efficiency amid revenue expansion. The significant EBITDA decline and margin compression suggest increased operational costs or pricing pressures that have impacted the company's profitability metrics during this reporting period.